The value of STEAP1, C-myc and P63 Immuno-expression in differentiation of prostatic carcinoma from its mimickers

Eman Fayad, Mahmoud Emara, Magdy Ahmed, Samar Abd El-Raouf
2019 Zagazig University Medical Journal  
Prostatic adenocarcinoma is the 2 nd most common cancer in males. It is important to differentiate between prostatic adenocarcinoma and its benign mimickers with novel and reliable immunohistochemical markers for early diagnosis of prostatic adenocarcinoma, (6-transmembrane epithelial antigen of prostate (STEAP1), C-myc and basal cell marker P63 can be helpful in distinguishing prostatic adenocarcinoma from benign lesions. The aim of this study is to diagnose prostatic adenocarcinoma and
more » ... ntiate it from its benign mimickers using STEAP1, C-myc and P63 immunoexpression and toevaluate the role of STEAP1 overexpression in prostate cancer initiation and progression. Methods: Retrospective cross-sectional study was conducted on 20 cases of prostatic adenocarcinoma, 8 cases of high grade prostatic intraepithelial neoplasia (HGPIN) and 18 cases of benign prostatic mimickers. All lesions were submitted for STEAP1, C-myc and P63 immunohistochemistry and the results were correlated with clinicopathological and histopathological parameters. Results: P63, STEAP1 and C-myc showed highly significant difference in expression in prostatic adenocarcinoma in relation to its benign mimickers (p-value<0.001). STEAP1 immunoexpression was significantly associated with Gleason score, grade grouping and perineural invasion of prostatic adenocarcinoma (p-value <0.05). Positive STEAP1 and Cmyc expression along with negative P63 showed high sensitivity (80.0%, 85.0% and 95.0%) respectively and considerable specificity (86.9%, 73.1% and 96.2%) respectively for differentiating between prostatic adenocarcinoma and its benign mimickers. Conclusion: STEAP1, C-myc and P63 immunoexpression was helpful in differentiation between prostatic adenocarcinoma and benign mimickers. STEAP1 may have a valuable prognostic role in prostatic adenocarcinoma.
doi:10.21608/zumj.2019.14012.1282 fatcat:rylzky4z6zfdrcd62ck4chhbvq